Cargando…
Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study
A total of 50 patients with advanced pancreatic cancer were enrolled in a phase II study of bevacizumab 15 mg kg(−1), capecitabine 1300 mg m(−2) daily for 2 weeks and gemcitabine 1000 mg m(−2) weekly 2 times; cycles were repeated every 21 days. Radiological response rate was 22%; progression-free su...
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2009
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2714236/ https://www.ncbi.nlm.nih.gov/pubmed/19491904 http://dx.doi.org/10.1038/sj.bjc.6605099 |